The collection of high-quality plasma from dedicated donors, like those in Texas, is a crucial component in the production of these therapies.
Past News ReleasesRSS
Texas (Vocus) August 19, 2009
The contributions of voluntary plasma donors and the issue of treating critically ill patients with plasma protein therapies was recognized by Texas lawmakers in June when they proclaimed August "Plasma Protein Therapies Month" in the Lone Star State.
"Patients requiring plasma protein therapies have serious diseases and disorders and need to be assured that they will continue to have access to those treatments," said Josh Penrod, Vice President, Source for the Plasma Protein Therapy Association. "The collection of high-quality plasma from dedicated donors, like those in Texas, is a crucial component in the production of these therapies."
Plasma protein therapies include a treatment for primary immunodeficiency diseases, alpha-1 antitrypsin deficiency, also known as genetic emphysema, and for blood clotting disorders such as hemophilia. In addition, a plasma protein therapy is used in critical care settings, when treating severe trauma, burns and during major surgery. Plasma protein therapies refer to plasma-derived therapies and their recombinant analogs.
Hundreds of Texans each year donate plasma at 48 collection centers in Texas to help create therapies that save the lives of thousands of people across the nation. In fact, Texas has the most plasma donation centers in the nation.
This recognition raises awareness of the rare, genetic diseases treated with the therapies and to honor plasma donors across the state for their contributions to the little known treatments that benefit patients with a variety of genetic diseases and those in critical care settings including trauma and major surgery.
The Plasma Protein Therapies Association, a trade association representing plasma protein therapy manufacturers and the source plasma collection industry.
The Plasma Protein Therapeutics Association (PPTA) is the trade association and standard setting organization for the world's major producers of plasma derived and recombinant analog therapies (collectively, "plasma protein therapies"). These therapies are used by more than 1 million people worldwide each year to treat a variety of diseases and serious medical conditions. PPTA members produce over 80 percent of the plasma therapies for the United States market and more than 60 percent worldwide. Some of the critical therapies produced by PPTA members include: blood clotting factors for people with hemophilia, immune globulin intravenous used to prevent infections in people with immune deficiencies and other serious conditions, and alpha 1 proteinase inhibitor used to treat people with alpha 1 antitrypsin deficiency, also known as genetic emphysema.
Kym H. Kilbourne
(443) 458 4682
(443) 995-2102 (cellular)